• Hepatocellular Carcinoma (HCC): ~75% of liver cancer
• ~50% of extrahepatic HCC patients have metastasis in lung
• Estimated global incidence rate of liver cancer: 9.3/100k people / year
• Mortality rate: 8.5
• Need a solution to reduce the growth of HCC and minimize metastasis

• Nidogen-1 specific antibody
• Good for neutralizing/blocking the functions of NID1 in liver cancer cell aggressive properties, tumor formation and metastasis
• Figure 1: Multiple injection of anti-nidogen-1 antibody (Ab#7) can reduce the formation of tumor in mouse model
• Figure 2: Single treatment of anti-nidogen-1 antibody (Ab#7) can reduce metastasis in lung in mouse model
  

Applications

• Research Tool for treatment of hepatocellular carcinoma

Opportunity

• Anti-nidogen-1 antibody is ready to delivery for researchers
• Developing treatment regime using anti-nidogen-1 antibody for liver cancer

• Regular US patent filing

• Patent application submitted